Protocol Summaries: GSK1605786
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 114203 | Phase 1 | A Single Dose, Randomized, Five-Period Crossover Study to Assess the Relative Bioavailability of Four New Formulations of the CCR9 Receptor Antagonist GSK1605786A (CCX282) in Healthy Male and Female Subjects | Completed |